TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis and Previously Treated With Biologic Anti- TNFa Agent(s)
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in subjects who have active rheumatoid arthritis and have been treated previously with at least 1 dose of a biologic anti-TNFa agent (etanercept, adalimumab or infliximab).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
B: Arm Label: Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Biological: Golimumab 50 mg | Arm Label: Group 2: Golimumab 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg | Arm Label: Group 3: Golimumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Group 1: Placebo, Group 2: Golimumab 50 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Group 3: Golimumab 100 mg
C: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
D: Arm Label: Placebo Plus Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Other: Placebo | Arm Label: Rituximab plus Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: MabThera/Rituxan, Drug: Methotrexate | Intervention Type: DRUG; Name: MabThera/Rituxan; Assigned to Arm(s): Rituximab plus Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Placebo Plus Methotrexate, Rituximab plus Methotrexate | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Plus Methotrexate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis and Previously Treated With Biologic Anti- TNFa Agent(s)
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in subjects who have active rheumatoid arthritis and have been treated previously with at least 1 dose of a biologic anti-TNFa agent (etanercept, adalimumab or infliximab).


Options:
A: Arm Label: ADA+MTX/PBO+MTX (Arm 1); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate, Biological: placebo | Arm Label: ADA+MTX/ADA+MTX (Arm2); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate | Arm Label: ADA+MTX/OL ADA+MTX (Arm 3); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate | Arm Label: PBO+MTX/PBO+MTX (Arm 4); Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Biological: placebo | Arm Label: PBO+MTX/OL ADA+MTX (Arm 5); Type: EXPERIMENTAL; Interventions: Biological: adalimumab, Drug: methotrexate, Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): ADA+MTX/ADA+MTX (Arm2), ADA+MTX/OL ADA+MTX (Arm 3), ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5) | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): ADA+MTX/ADA+MTX (Arm2), ADA+MTX/OL ADA+MTX (Arm 3), ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5), PBO+MTX/PBO+MTX (Arm 4) | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): ADA+MTX/PBO+MTX (Arm 1), PBO+MTX/OL ADA+MTX (Arm 5), PBO+MTX/PBO+MTX (Arm 4)
B: Arm Label: Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Biological: Golimumab 50 mg | Arm Label: Group 2: Golimumab 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg | Arm Label: Group 3: Golimumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Group 1: Placebo, Group 2: Golimumab 50 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Group 3: Golimumab 100 mg
C: N/A
D: Arm Label: Sequence 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: CP-690,550 or Placebo | Arm Label: Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550 or Placebo; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients?
Brief Summary: Hyperphosphatemia is frequently seen in patients with end-stage renal disease (ESRD). Hyperphosphatemia usually results in a high calcium-phosphorus product (CPP) which may subsequently lead to artery and become a risk factor of cardiovascular complications. Alendronate, due to its effect of inhibiting osteoclasts, is approved for treatment of osteoporosis. Previous reports found the use of bisphosphonates could suppress arterial calcification in hemodialysis dialysis patients. The aim of this study is to evaluate the safety and efficacy of alendronate to suppress coronary artery and aortic calcifications, as well as to improve bone density in chronic peritoneal dialysis (PD) patients.

This study will include ESRD patients who had received maintenance PD for more than 3 months, have high CPP level (≧55), and have chest X-ray proven aortic calcification or coronary artery calcification. All participants are randomly allocated to either group 1 or group 2. Group 1 patients receive alendronate 70 mg once weekly in the first 16 weeks, while group 2 patients receive the same dose of drug every week in the second 16 weeks. The extent of coronary artery and aortic calcification is evaluated by using multi-detector spiral computed tomography, whereas bone mineral density is measured by dual-energy X-ray absorptiometry. Both examinations are performed at week 0, 16 and 32 for each participant. Laboratory studies and possible adverse reactions were regularly monitored.

We expect that alendronate can alleviate the progression of arterial calcification or even improve it. Bone density may also be improved after treatment. Besides, we wish to find the independent factor(s) influencing the efficacy of alendronate. These results may help clinical physicians for early intervention and prevention of cardiovascular complications in ESRD patients.


Options:
A: Intervention Type: DRUG; Name: alendronate (Fosamax); Assigned to Arm(s): N/A
B: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl (placebo) | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab | Intervention Type: DRUG; Name: NaCl (placebo); Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alendronate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Denosumab 60 mg Q6M; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab 60 mg Q6M

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients
Brief Summary: The use of neuromuscular blocking agents (NMBA) in ARDS patients has not been extensively investigated. The aim of the study is to show a reduction of the mortality rate of ARDS patients.


Options:
A: Arm Label: Mesenchymal stem cell arm; Type: EXPERIMENTAL; Interventions: Drug: Mesenchymal stem cells | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mesenchymal stem cells; Assigned to Arm(s): Mesenchymal stem cell arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells; Type: EXPERIMENTAL; Interventions: Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells | Intervention Type: BIOLOGICAL; Name: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells; Assigned to Arm(s): Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisatracurium, Drug: Cisatracurium besilate | Intervention Type: DRUG; Name: cisatracurium; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cisatracurium besilate; Assigned to Arm(s): B
D: Arm Label: Part A; Type: EXPERIMENTAL; Interventions: Drug: Dose 1 GSK2586881, Drug: Dose 2 GSK2586881, Drug: Dose 3 GSK2586881, Drug: Dose 4 GSK2586881 | Arm Label: Part B; Type: EXPERIMENTAL; Interventions: Drug: Dose 3 GSK2586881, Drug: Placebo (saline) | Intervention Type: DRUG; Name: Dose 1 GSK2586881; Assigned to Arm(s): Part A | Intervention Type: DRUG; Name: Dose 2 GSK2586881; Assigned to Arm(s): Part A | Intervention Type: DRUG; Name: Dose 3 GSK2586881; Assigned to Arm(s): Part A, Part B | Intervention Type: DRUG; Name: Dose 4 GSK2586881; Assigned to Arm(s): Part A | Intervention Type: DRUG; Name: Placebo (saline); Assigned to Arm(s): Part B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients
Brief Summary: The use of neuromuscular blocking agents (NMBA) in ARDS patients has not been extensively investigated. The aim of the study is to show a reduction of the mortality rate of ARDS patients.


Options:
A: Intervention Type: DRUG; Name: Mythylprednisolone; Assigned to Arm(s): N/A
B: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisatracurium, Drug: Cisatracurium besilate | Intervention Type: DRUG; Name: cisatracurium; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cisatracurium besilate; Assigned to Arm(s): B
C: Arm Label: One Group; Type: N/A; Interventions: N/A
D: Arm Label: Conventional Ventilation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lung Protective Ventilation | Arm Label: High Frequency Oscillation; Type: EXPERIMENTAL; Interventions: Device: SensorMedics 3100B High Frequency Oscillatory Ventilator | Intervention Type: DEVICE; Name: SensorMedics 3100B High Frequency Oscillatory Ventilator; Assigned to Arm(s): High Frequency Oscillation | Intervention Type: PROCEDURE; Name: Lung Protective Ventilation; Assigned to Arm(s): Conventional Ventilation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients
Brief Summary: The use of neuromuscular blocking agents (NMBA) in ARDS patients has not been extensively investigated. The aim of the study is to show a reduction of the mortality rate of ARDS patients.


Options:
A: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
B: Arm Label: IgM-enriched Intravenous Immunoglobulins; Type: ACTIVE_COMPARATOR; Interventions: Drug: IgM-enriched Intravenous Immunoglobulins | Arm Label: Human Albumin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Human Albumin | Intervention Type: DRUG; Name: IgM-enriched Intravenous Immunoglobulins; Assigned to Arm(s): IgM-enriched Intravenous Immunoglobulins | Intervention Type: DRUG; Name: Human Albumin; Assigned to Arm(s): Human Albumin
C: Arm Label: NMES; Type: EXPERIMENTAL; Interventions: Device: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA) | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Intervention Type: DEVICE; Name: Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA); Assigned to Arm(s): NMES | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisatracurium, Drug: Cisatracurium besilate | Intervention Type: DRUG; Name: cisatracurium; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cisatracurium besilate; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal® Consta® and Abilify® (Aripiprazole) in Adults With Schizophrenia
Brief Summary: The purpose of this study is to compare the effectiveness of two antipsychotic medications, RisperdalÂ® ConstaÂ® versus AbilifyÂ®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.


Options:
A: Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abilify | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidal Consta | Intervention Type: DRUG; Name: Abilify; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Risperidal Consta; Assigned to Arm(s): 001
B: Arm Label: RISPERDAL CONSTA; Type: ACTIVE_COMPARATOR; Interventions: Drug: RISPERDAL CONSTA | Arm Label: R092670; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone palmitate | Intervention Type: DRUG; Name: RISPERDAL CONSTA; Assigned to Arm(s): RISPERDAL CONSTA | Intervention Type: DRUG; Name: Paliperidone palmitate; Assigned to Arm(s): R092670
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: IM risperidone | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral antipsychotic medication | Intervention Type: DRUG; Name: IM risperidone; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: oral antipsychotic medication; Assigned to Arm(s): Arm 2
D: Arm Label: Risperidone LAI; Type: OTHER; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone LAI

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A DB, Randomized, Placebo-controlled Study of the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial CLBS14 for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of intramyocardial injections of CLBS14 in patients with refractory chronic myocardial ischemia.


Options:
A: Intervention Type: GENETIC; Name: Cell Therapy - Autologous CD34 Positive Cells; Assigned to Arm(s): N/A
B: Arm Label: Stem Cell Therapy; Type: EXPERIMENTAL; Interventions: Device: Intramyocardial Injection of stem cells via NOGA Mapping | Arm Label: Control, then Stem Cell Therapy; Type: OTHER; Interventions: Other: Control, then Stem Cell Therapy | Intervention Type: DEVICE; Name: Intramyocardial Injection of stem cells via NOGA Mapping; Assigned to Arm(s): Stem Cell Therapy | Intervention Type: OTHER; Name: Control, then Stem Cell Therapy; Assigned to Arm(s): Control, then Stem Cell Therapy
C: Arm Label: CLBS14: Low-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: CLBS14 (low-dose) | Arm Label: CLBS14: High-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: CLBS14 (high-dose) | Arm Label: Placebo injection; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo injection | Intervention Type: BIOLOGICAL; Name: CLBS14 (low-dose); Assigned to Arm(s): CLBS14: Low-Dose Group | Intervention Type: BIOLOGICAL; Name: CLBS14 (high-dose); Assigned to Arm(s): CLBS14: High-Dose Group | Intervention Type: BIOLOGICAL; Name: placebo injection; Assigned to Arm(s): Placebo injection
D: Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Biological: Auto-CD34+ cells | Arm Label: Active Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo: Diluent used to suspend Auto-CD34+ cells | Arm Label: Unblinded Standard of Care (SOC) Arm; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: BIOLOGICAL; Name: Auto-CD34+ cells; Assigned to Arm(s): Treatment Arm | Intervention Type: BIOLOGICAL; Name: Placebo: Diluent used to suspend Auto-CD34+ cells; Assigned to Arm(s): Active Control Arm | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Unblinded Standard of Care (SOC) Arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
Brief Summary: The purpose of the study is to assess the efficacy and safety of NGX-4010 applied for 60 minutes for the treatment of postherpetic neuralgia (PHN).


Options:
A: Intervention Type: DRUG; Name: NGX-4010; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Capsaicin Dermal Patch; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Improving Care of Acute Lung Injury Patients (ICAP) Study
Brief Summary: Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a severe lung condition that causes respiratory failure. Individuals with ALI/ARDS often require the use of a respirator or artificial breathing machine, known as a mechanical ventilator, while in an intensive care unit (ICU). Past research has shown that improved short-term clinical outcomes result from the use of a protective mechanical ventilation technique for the lungs. This study will evaluate the effects of lower tidal volume ventilation, and other aspects of critical illness and ICU care, on the long-term clinical outcomes of individuals with ALI/ARDS.


Options:
A: N/A
B: N/A
C: N/A
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Pulmonary Rehabilitation | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Improving Care of Acute Lung Injury Patients (ICAP) Study
Brief Summary: Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a severe lung condition that causes respiratory failure. Individuals with ALI/ARDS often require the use of a respirator or artificial breathing machine, known as a mechanical ventilator, while in an intensive care unit (ICU). Past research has shown that improved short-term clinical outcomes result from the use of a protective mechanical ventilation technique for the lungs. This study will evaluate the effects of lower tidal volume ventilation, and other aspects of critical illness and ICU care, on the long-term clinical outcomes of individuals with ALI/ARDS.


Options:
A: Arm Label: Focal ARDS; Type: EXPERIMENTAL; Interventions: Procedure: Mechanical ventilation | Arm Label: non focal ARDS; Type: OTHER; Interventions: Procedure: Mechanical ventilation | Intervention Type: PROCEDURE; Name: Mechanical ventilation; Assigned to Arm(s): Focal ARDS, non focal ARDS
B: Intervention Type: DEVICE; Name: High-frequency oscillation; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Conventional lung-open mechanical ventilation; Assigned to Arm(s): N/A
C: N/A
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisatracurium, Drug: Cisatracurium besilate | Intervention Type: DRUG; Name: cisatracurium; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cisatracurium besilate; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Assessing the efficacy of escitalopram in preventing the development of PTSD, or or reducing its severeness, after exposure to a traumatic event.


Options:
A: Arm Label: Ketamine arm; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Ketamine arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo arm
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Neuropeptide Y; Type: ACTIVE_COMPARATOR; Interventions: Drug: Neuropeptide Y | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Neuropeptide Y; Assigned to Arm(s): Neuropeptide Y | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Control Arm - Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Arm - Propranolol hydrochloride; Type: EXPERIMENTAL; Interventions: Drug: Propranolol Hydrochloride | Intervention Type: DRUG; Name: Propranolol Hydrochloride; Assigned to Arm(s): Intervention Arm - Propranolol hydrochloride

Answer: C